摘要
目的研究原发性肝细胞癌(pri mary hepatocellular carcinoma,PHC)组织中多药耐药基因P-糖蛋白(P-glycoprotein,P-gp)、拓扑异构酶Ⅱα(topoisomeraseⅡalpha,TopoⅡα)和P53的表达及共表达情况,分析其表达与PHC临床特征的关系。方法采用免疫组织化学SP法检测P-gp、TopoⅡα和P53的表达,并结合临床特征进行分析。结果 P-gp、TopoⅡα和P53阳性表达率分别为80.74%(109/135)、46.67%(63/135)和33.33%(45/135),P-gp阳性率明显高于TopoⅡα、P53(P=0.000),TopoⅡα阳性率高于P53(P<0.05)。P-gp阳性率与患者年龄、肿瘤细胞分化程度、肿瘤大小有关,患者血清AFP升高者P-gp、TopoⅡα阳性率均高于AFP正常者(P<0.05),血清AST升高者P-gp、P53阳性率均高于AST正常者(P<0.05)。TopoⅡα和P53阳性率与患者年龄、肿瘤细胞分化程度、肿瘤大小无关(P>0.05)。两种和三种基因产物共表达阳性率为51.85%(70/135),明显高于单一基因产物表达阳性率34.07%(χ2=8.706,P<0.01)。结论肝癌多药耐药是由多种耐药基因产物共同作用的结果,单基因和多基因共同作用,以多基因共表达为主。联合检测肝癌患者的多药耐药基因产物,对于临床合理用药、提高化疗疗效具有指导意义。
Objective To explore the expression of P-glycoprotein（P-gp）,topoisomerase Ⅱ alpha（TopoⅡα）,P53 in primary hepatocellular carcinoma（PHC） and their correlations with clinical characteristics.Methods The expressions of P-gp,TopoⅡα and P53 were detected by means of SP immunohistochemical technique in 135 cases of PHC.Results The positive rates of P-gp,TopoⅡα and P53 were 80.74%（109/135）,46.67%（63/135）,33.33%（45/135） respectively.The positive rate of P-gp was higher than that of TopoⅡα or P53（P=0.000）.The positive rate of TopoⅡα was higher than that of P53（P0.05）.The expression of P-gp was related to age,tumor differentiation and tumor size.The expressions of P-gp and TopoⅡα were higher in cases with AFP-elevated than those of AFP-normal（P0.05）.The expressions of P-gp and P53 were higher in cases with AST-elevated than those of AST-normal（P0.05）.The expressions of TopoⅡα and P53 weren＇t related to age,tumor differentiation and tumor size（P0.05）.The co-expression rate of multidrug resistant genes was 51.85%（70/135）.The co-expression rate was higher than individual expression rate（34.07%,χ2=8.706,P0.01）.Conclusion The multidrug resistance of PHC is affected by various multidrug resistance genes.There is synergistic effect between single and multiple genes,co-expression of multiple genes mainly.It is important that detection of their expressions may guide the clinical use of drugs and predicate chemotherapy effects.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2011年第3期278-280,285,共4页
Cancer Research on Prevention and Treatment
基金
广东省自然科学基金资助项目(07117591)
